On February 8, 2021, Suzhou Basecare Medical Corporation Limited ("Basecare Medical", stock code: 2170.HK) as successfully listed on the Main Board of the Stock Exchange of Hong Kong Ltd. Globally, Basecare Medical offered 66,667,000 shares. The offering price was set at HK$27.36 per share and was at the upper limit of the offer price, and it raised about HK$1.8 billion in total. Basecare Medical's project is Tian Yuan's 11th project of unprofitable biotechnology company listed in Hong Kong.
As a China legal adviser to the issuer of Basecare Medical, Tian Yuan effectively advised the company in designing, implementing the restructuring and stock reform program. Within two months or so after the start of the project, Tian Yuan advised the company complete the restructuring, stock reform and submitted listing application documents to CSRC and the Stock Exchange of Hong Kong Limited. After that, it advises the project in obtaining domestic and foreign approvals smoothly. With high-quality, professional and practical legal services, it will eventually advise Basecare Medical to successfully land onto the Hong Kong's capital market.